Abstract
As a major threat among women globally, breast cancer (BC) emerges as a primary research focus for several researchers. Although various therapeutic regimens are available, there is an increased chance of metastasis of BC cells, which raises the severity of this malignancy. Of multiple preferred secondary targets, metastasis to bone is extensively studied. Besides deemed as a bone transcription factor, Runx2 also acts as a metastatic factor that promotes growth and metastasis of BC cells. Studies have reported the significant role of microRNAs (miRNAs) in BC pathogenesis and metastasis by governing Runx2 expression. Additionally, dysregulation of the signaling pathways, including Wnt/β-catenin, TGF-β, Notch, and PI3K/AKT, has been observed to influence the expression of Runx2 in BC cells. In this review, we have aimed to highlight the regulatory role of miRNAs in targeting Runx2 both directly and indirectly by governing respective signaling pathways during bone metastasis of BC.
Keywords: Breast pathogenesis, non-coding RNAs, osteolytic metastasis, post-transcriptional regulation, signal transduction, transcription factor.
Graphical Abstract
Current Protein & Peptide Science
Title:Regulation of Runx2 and Its Signaling Pathways by MicroRNAs in Breast Cancer Metastasis
Volume: 22 Issue: 7
Author(s): Shivashankar Pranavkrishna, Ganesh Sanjeev, Ravishkumar L. Akshaya, Muthukumar Rohini and Nagarajan Selvamurugan*
Affiliation:
- Department of Biotechnology, College of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu,India
Keywords: Breast pathogenesis, non-coding RNAs, osteolytic metastasis, post-transcriptional regulation, signal transduction, transcription factor.
Abstract: As a major threat among women globally, breast cancer (BC) emerges as a primary research focus for several researchers. Although various therapeutic regimens are available, there is an increased chance of metastasis of BC cells, which raises the severity of this malignancy. Of multiple preferred secondary targets, metastasis to bone is extensively studied. Besides deemed as a bone transcription factor, Runx2 also acts as a metastatic factor that promotes growth and metastasis of BC cells. Studies have reported the significant role of microRNAs (miRNAs) in BC pathogenesis and metastasis by governing Runx2 expression. Additionally, dysregulation of the signaling pathways, including Wnt/β-catenin, TGF-β, Notch, and PI3K/AKT, has been observed to influence the expression of Runx2 in BC cells. In this review, we have aimed to highlight the regulatory role of miRNAs in targeting Runx2 both directly and indirectly by governing respective signaling pathways during bone metastasis of BC.
Export Options
About this article
Cite this article as:
Pranavkrishna Shivashankar , Sanjeev Ganesh, Akshaya L. Ravishkumar , Rohini Muthukumar and Selvamurugan Nagarajan *, Regulation of Runx2 and Its Signaling Pathways by MicroRNAs in Breast Cancer Metastasis, Current Protein & Peptide Science 2021; 22 (7) . https://dx.doi.org/10.2174/1389203721666201116115337
DOI https://dx.doi.org/10.2174/1389203721666201116115337 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Cancer Therapy Reviews Whole Organism Based Techniques and Approaches in Early Stage Oncology Drug Discovery-Patents and Trends
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cells
Current Drug Targets Retinoic Acid Metabolism and Mechanism of Action: A Review
Current Drug Metabolism Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors
Mini-Reviews in Medicinal Chemistry Absorption, Pharmacokinetics and Disposition of Biodegradable Nanoscale Preparations
Current Drug Metabolism Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study
Current HIV Research Cancer and the Endogenous “Pineal Clock”: A Means of Early Diagnosis and Successful Treatment as Well as Prevention of Cancers
Current Aging Science State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets The Biochemical Mechanisms of T-Cell Anergy
Current Immunology Reviews (Discontinued) Biosafety of Lentiviral Vectors
Current Gene Therapy Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review
Current Pharmaceutical Design Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma
Anti-Cancer Agents in Medicinal Chemistry